BioLineRx (NASDAQ:BLRX – Get Free Report) is expected to release its Q4 2025 results before the market opens on Monday, March 23rd. Analysts expect the company to announce earnings of ($0.50) per share and revenue of $0.4920 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Monday, March 23, 2026 at 8:30 AM ET.
BioLineRx Price Performance
NASDAQ:BLRX opened at $2.65 on Friday. The company has a market cap of $11.53 million, a P/E ratio of 15.59 and a beta of 1.31. The firm’s fifty day moving average price is $2.86 and its two-hundred day moving average price is $3.27. BioLineRx has a one year low of $2.30 and a one year high of $7.77. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.09 and a quick ratio of 1.93.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of BioLineRx in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, BioLineRx currently has an average rating of “Moderate Buy” and an average target price of $26.00.
About BioLineRx
BioLineRx (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company that discovers and develops novel small-molecule therapies to address unmet medical needs. The company focuses on identifying promising drug candidates through licensing and collaboration agreements with academic institutions and biotech innovators, then advancing these candidates through preclinical and clinical development stages. BioLineRx’s pipeline spans oncology, immunology and inflammatory diseases, central nervous system disorders and pain management.
Among its clinical programs, BioLineRx is advancing targeted cancer therapies designed to improve outcomes for patients with difficult-to-treat tumors.
Read More
Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.
